Agricultural Opportunities
Executive Summary
Millennium's recent blockbuster deal with Monsanto isn't in healthcare--it's in agriculture. Now other drug-oriented biotechs are considering whether they too can leverage their discovery assets this way. Some firms believe their technologies are directly translatable; others say ag companies can't afford to pay for the methods. The big question: whether to do exclusive deals.
You may also be interested in...
How Significant Will Veklury’s Sales Be? Forecasts Show It Is Hard To Tell
Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.
Brexit: Life Science Firms In An ‘Impossible Position’
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
Novartis Advances Novel Kidney Disease Therapy Iptacopan
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Need a specific report? 1000+ reports available
Buy Reports